Robert M. Angert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert M. Angert has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna S. Cosnahan
Department of Pharmacy, Indiana University Health, Indianapolis, Indiana, United States
1 shared publication Edward Ebani
Yeshiva University
1 shared publicationElena V. Wachtel
Department of Pediatrics, NYU Grossman School of Medicine, New York, NY, USA
1 shared publicationEni Jano
Department of Pediatrics, NYU Grossman School of Medicine, New York, NY, USA
1 shared publication- Irena Tsui
UCLA Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
1 shared publication Jamie B. Rosenberg
Ophthalmology & Visual Sciences
1 shared publication
Latest Publications
- 11 February 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (6) , 809-814
Part 5: Essentials of Neonatal-Perinatal Medicine Fellowship: evaluation of competence and proficiency using Milestones
The Accreditation Council for Graduate Medical Education (ACGME) Pediatric Subspecialty Milestone Project competencies are used for Neonatal-Perinatal Medicine (NPM) fellows. Milestones are longitudinal markers that range from novice to expert (levels 1–5). There is no standard approach to the required biannual evaluation of fellows by fellowship programs, resulting in significant variability among programs regarding procedural experience and exposure to pathology during clinical training. In this paper, we discuss the opportunities that Milestones provide, potential strategies to address challenges, and future directions.
- 11 February 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (6) , 809-814
Part 5: Essentials of Neonatal-Perinatal Medicine Fellowship: evaluation of competence and proficiency using Milestones
The Accreditation Council for Graduate Medical Education (ACGME) Pediatric Subspecialty Milestone Project competencies are used for Neonatal-Perinatal Medicine (NPM) fellows. Milestones are longitudinal markers that range from novice to expert (levels 1–5). There is no standard approach to the required biannual evaluation of fellows by fellowship programs, resulting in significant variability among programs regarding procedural experience and exposure to pathology during clinical training. In this paper, we discuss the opportunities that Milestones provide, potential strategies to address challenges, and future directions.
- 1 March 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (9) , 2284-2291
Dexmedetomidine versus intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia
Objective In March 2019, the sedative in the therapeutic hypothermia protocol at Bellevue Hospital Center and NYU Langone Health changed from morphine to dexmedetomidine. This study evaluated the impact of this change on efficacy and safety parameters. Study design This was a retrospective, observational cohort study including neonates with HIE undergoing therapeutic hypothermia (N = 70) at two regional perinatal medical centers. Results Baseline demographics, pain scores, hemodynamics, and time to enteral feeds were similar between dexmedetomidine (N = 34) and morphine (N = 36) patients. Dexmedetomidine patients received more breakthrough morphine (0.13 ± 0.13 vs 0.04 ± 0.09 mg/kg, p = 0.001), but less cumulative morphine (0.13 ± 0.13 vs 1.79 ± 0.23 mg/kg, p < 0.0001). Morphine patients on invasive ventilation required increased support (0 vs 31.58%, p = 0.02). Conclusion Dexmedetomidine is effective and safe for sedation and analgesia during therapeutic hypothermia. It reduced total opioid usage, with no increased incidence of adverse events.
- 1 March 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (9) , 2284-2291
Dexmedetomidine versus intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia
Objective In March 2019, the sedative in the therapeutic hypothermia protocol at Bellevue Hospital Center and NYU Langone Health changed from morphine to dexmedetomidine. This study evaluated the impact of this change on efficacy and safety parameters. Study design This was a retrospective, observational cohort study including neonates with HIE undergoing therapeutic hypothermia (N = 70) at two regional perinatal medical centers. Results Baseline demographics, pain scores, hemodynamics, and time to enteral feeds were similar between dexmedetomidine (N = 34) and morphine (N = 36) patients. Dexmedetomidine patients received more breakthrough morphine (0.13 ± 0.13 vs 0.04 ± 0.09 mg/kg, p = 0.001), but less cumulative morphine (0.13 ± 0.13 vs 1.79 ± 0.23 mg/kg, p < 0.0001). Morphine patients on invasive ventilation required increased support (0 vs 31.58%, p = 0.02). Conclusion Dexmedetomidine is effective and safe for sedation and analgesia during therapeutic hypothermia. It reduced total opioid usage, with no increased incidence of adverse events.
- 14 February 2014
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 45 (2) , 138-142
Trends in Retinopathy of Prematurity Over a 5-Year Period in a Racially Diverse Population
BACKGROUND AND OBJECTIVE: Retinopathy of prematurity presents differently in developing versus developed countries, which may be due to environmental as well as racial differences. PATIENTS AND METHODS: Retrospective chart review of infants screened for ROP at a single neonatal intensive care unit. Risk factors were reviewed. Main outcome measures were rates of plus disease or treatment-requiring ROP by race. RESULTS: The study included 497 infants screened for ROP in an urban neonatal intensive care unit. Gestational age, birth weight, and bronchopulmonary dysplasia were independent risk factors for both plus disease and treatment-requiring ROP with type 3 multivariate analysis. Self-identified white race was also a risk factor for plus disease and treatment-requiring ROP. Race was significantly associated with maternal age, multiple births, and blood transfusions. CONCLUSION: In the study population, white race was an independent risk factor for plus disease and ROP treatment. [ Ophthalmic Surg Lasers Imaging Retina . 2014;45:138–142.]
- 14 February 2014
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 45 (2) , 138-142
Trends in Retinopathy of Prematurity Over a 5-Year Period in a Racially Diverse Population
BACKGROUND AND OBJECTIVE: Retinopathy of prematurity presents differently in developing versus developed countries, which may be due to environmental as well as racial differences. PATIENTS AND METHODS: Retrospective chart review of infants screened for ROP at a single neonatal intensive care unit. Risk factors were reviewed. Main outcome measures were rates of plus disease or treatment-requiring ROP by race. RESULTS: The study included 497 infants screened for ROP in an urban neonatal intensive care unit. Gestational age, birth weight, and bronchopulmonary dysplasia were independent risk factors for both plus disease and treatment-requiring ROP with type 3 multivariate analysis. Self-identified white race was also a risk factor for plus disease and treatment-requiring ROP. Race was significantly associated with maternal age, multiple births, and blood transfusions. CONCLUSION: In the study population, white race was an independent risk factor for plus disease and ROP treatment. [ Ophthalmic Surg Lasers Imaging Retina . 2014;45:138–142.]